Adiana is a technology company.
Adiana is a technology company.
Adiana has raised $23.0M across 1 funding round.
Adiana has raised $23.0M in total across 1 funding round.
Adiana has raised $23.0M in total across 1 funding round.
Adiana's investors include Lightspeed Venture Partners, OrbiMed.
Adiana was a medical technology company that developed a non-surgical permanent contraception system using radiofrequency (RF) energy to occlude the fallopian tubes, preventing pregnancy.[1][2][3] It targeted women seeking a minimally invasive alternative to traditional tubal ligation, addressing the need for safer, outpatient sterilization options with quicker recovery.[2][3] The company, clinically driven and focused on innovative technologies to improve quality of life, achieved significant growth momentum through FDA approval pursuits and a major acquisition by Cytyc Corporation in 2007 for up to $215 million.[1][2]
Founded in the early 2000s in Redwood City, California, Adiana emerged from the need for advanced female sterilization methods beyond invasive surgery.[2] Key details on specific founders are not detailed in available records, but the company quickly gained traction by developing its proprietary RF-based system, which delivered energy via a catheter to create controlled tissue scarring for tube blockage.[1][3] A pivotal moment came in 2007 when the product awaited U.S. FDA approval, leading to its acquisition by Cytyc Corporation, validating early innovation in women's health tech.[2][3]
Adiana rode the early 2000s wave of minimally invasive medical devices, capitalizing on trends in outpatient gynecology and women's health innovation amid rising demand for less traumatic fertility control options.[1][2] Timing was ideal post-advances in RF energy applications, with market forces favoring devices that cut surgical costs and complications.[3] It influenced the ecosystem by pioneering non-incisional sterilization, paving the way for subsequent technologies in reproductive health medtech.
Post-2007 acquisition by Cytyc (later integrated into Hologic), Adiana's core technology was absorbed into larger portfolios, with its legacy enduring in modern hysteroscopic sterilization methods.[2] Future influence lies in ongoing evolutions of RF-based contraception amid telemedicine and personalized medtech trends, potentially inspiring next-gen devices for global women's health access. This clinically driven innovator set a benchmark for tech-enabled quality-of-life improvements in a field still ripe for disruption.
Adiana has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series D in August 2005.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2005 | $23.0M Series D | Lightspeed Venture Partners, OrbiMed |